Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting
- Written by PR Newswire
BEIJING, SHANGHAI, and SAN DIEGO, April 9, 2024 /PRNewswire/ -- Jacobin Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivator JAB-30355 in form of the abstract during the...